Eloxx Pharmaceuticals (NASDAQ:ELOX) Upgraded by Zacks Investment Research to Hold

0
45

Eloxx Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Eloxx Pharmaceuticals Upgraded by Zacks Investment Research on 10/19/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

Shares of Eloxx Pharmaceuticals traded down -$0.01 on Tuesday, reaching $1.48. 145459 shares of the stock traded hands, compared to its average volume of 657730. Shares of Eloxx Pharmaceuticals were trading at $1.48 on Tuesday. The firm’s 50 day moving average is $1.57 and its 200 day moving average is $2.40.Eloxx Pharmaceuticals has a 12 month low of $1.45 and a 12 month high of $6.77. While on yearly highs and lows, Eloxx Pharmaceuticals’s today has traded high as $1.51 and has touched $1.45 on the downward trend. See More Analyst Rating at: RATING

Eloxx Pharmaceuticals Earnings and What to expect: 

Eloxx Pharmaceuticals last announced its earnings data on August 15th, 2021. The reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by $0.07. Eloxx Pharmaceuticals has generated ($0.86) earnings per share over the last year (($1.07) diluted earnings per share). Earnings for Eloxx Pharmaceuticals are expected to grow in the coming year, from ($0.70) to ($0.60) per share. Eloxx Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 4th, 2021 based off prior year’s report dates.

Earnings for Eloxx Pharmaceuticals are expected to grow in the coming year, from ($0.70) to ($0.60) per share. The P/E ratio of Eloxx Pharmaceuticals is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Eloxx Pharmaceuticals is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Eloxx Pharmaceuticals has a P/B Ratio of 5.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Eloxx Pharmaceuticals (NASDAQ:ELOX) Moving Average Technical Analysis

5 day Moving Average is $1.53 And 5 day price change is -$0.10 (-6.33%)  with average volume for 5 day average is 160,740. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $1.62 and 20 day price change is -$0.30 (-16.85%) and average 20 day moving volume is 298,330. 50 day moving average is $1.57  and 50 day price change is $0.09 ( 6.47%)  and with average volume for 50 days is : 578,836. 200 day moving average is $2.40  and 200 day price change is -$2.38 (-61.66%)  and with average volume for 200 days is : 897,778.

Other owners latest trading in Eloxx Pharmaceuticals :

  • On 10/14/2021 shares held by Private Advisor Group LLC were 32,510 which equates to market value of $52K and appx 0.00% owners of Eloxx Pharmaceuticals
  • On 8/23/2021 shares held by Morgan Stanley were 20,161 which equates to market value of $39K and appx 0.00% owners of Eloxx Pharmaceuticals
  • On 8/17/2021 shares held by Wells Fargo & Company MN were 21,455 which equates to market value of $43K and appx 0.00% owners of Eloxx Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 34.84% for Eloxx Pharmaceuticals

See More Analyst Rating at: RATING